Login to Your Account



Twice the Drugs, Twice the Cost

Oncology Drug Combinations Face Pushback from Payers

By Brian Orelli
BioWorld Insight Contributing Writer

Monday, November 19, 2012

Oncology drugs are expensive enough on their own. When they start getting used in succession, the cost per patient can really start to add up, causing companies to feel pushback from payers.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription